Načítá se...
Evidence-Based Minireview: What is the optimal timing of anti–PD-1 antibodies in relapsed classical Hodgkin lymphoma?
A 26-year-old woman was initially diagnosed with stage III classical Hodgkin lymphoma (HL) treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) for 6 cycles and relapsed 9 months after completing therapy. She was treated with salvage chemotherapy followed by an autologous transpl...
Uloženo v:
| Vydáno v: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society of Hematology
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913434/ https://ncbi.nlm.nih.gov/pubmed/31808863 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000077 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|